Science & Pipeline

BioShin is a clinical-stage company focused on advancing therapies in China and the Asia-Pacific region for which there are currently limited adequate treatment options.

Our current clinical programs span a range of innovative, late-stage product candidates targeting neurological diseases. BioShin combines internal assets with intellectual property licensed from leading biopharma companies and academic institutions to rapidly progress multiple compounds in clinical trials across three platforms: calcitonin gene-related peptide (CGRP) receptor antagonism, glutamate modulation, and myeloperoxidase (MPO) inhibition.

Our Platforms

Calcitonin gene-related peptide (CGRP) receptor antagonists are a class of drug candidates that act to block the pain signaling pathway. Oral CGRP antagonists have the potential to be best in class therapy for migraine and other CGRP-mediated disorders.

Glutamate is present in 90% of brain synapses, and plays a critical role in neurotransmission.

The myeloloperoxidase (MPO) enzyme is a key driver of oxidative and inflammatory processes that drive neuroinflammation and underlie the causes of neurodegeneration.

Our Pipeline-Clinical Stage

PLANTFORM
DRUG NAME
PRECLINICAL
PHASE 1
PHASE 2
PHASE 3
MARKETED
CALCITONIN GENE-RELATED PEPTIDE (CGRP)

Rimegepant

Small molecule/NCE
NURTEC ODT | China / Korea program - Acute Migraine
NURTEC ODT | Trigeminal Neuralgia
NURTEC ODT | Plaque Psoriasis
NURTEC ODT | additional pain and atopic diseases under consideration*

Zavegepant

Small molecule/NCE
Intranasal | Acute Migraine
undisclosed
GLUTAMATE

Troriluzole

NCE
Spinocerebellar Ataxia (SCA)
Obsessive-Compulsive Disorder (OCD)

BHV-5000/5500

NCE NMDA antagonist
Topical | Peripheral Neuralgia
MYELOPEROXIDASE (MPO)

Verdiperstat

NCE oral MPO inhibitor
Multiple System Atrophy (MSA)
Amyotrophic Lateral Sclerosis (ALS)